Acumen Pharmaceuticals (NASDAQ: ABOS) net income
Acumen Pharmaceuticals reported a net loss of $121.3m for fiscal 2025; in fiscal 2024 it reported a net loss of $102.3m. Earnings per share were −$2.00.
Acumen Pharmaceuticals's best year of the last 6 was fiscal 2020. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$121.3m | — | — | −$2.00 |
| 2024 | −$102.3m | — | — | −$1.71 |
| 2023 | −$52.4m | — | −485.3% | −$1.08 |
| 2022 | −$42.9m | — | −1,791.6% | −$1.06 |
| 2021 | −$100.6m | — | — | −$5.02 |
| 2020 | −$7.3m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Acumen Pharmaceuticals net income compared with its sector
By net income for its latest fiscal year, Acumen Pharmaceuticals ranks 356th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 354th | Voyager Therapeutics | −$119.7m | −296.5% |
| 355th | TYRA Biosciences | −$119.9m | — |
| 356th | Acumen Pharmaceuticals | −$121.3m | — |
| 357th | Tilray Brands | −$121.4m | −13.3% |
| 358th | Trulieve Cannabis | −$122.2m | −10.3% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Acumen Pharmaceuticals
- How much did Acumen Pharmaceuticals earn in fiscal 2025?
- Acumen Pharmaceuticals reported a net loss of $121.3m for fiscal 2025. In fiscal 2024 it reported a net loss of $102.3m.
- What are the earnings per share of Acumen Pharmaceuticals?
- They were −$2.00 in fiscal 2025, compared with −$1.71 in fiscal 2024.
- Where does Acumen Pharmaceuticals rank in its sector by net income?
- It ranks 356th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Acumen Pharmaceuticals come from?
- From the annual report (Form 10-K) that Acumen Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Acumen Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Acumen Pharmaceuticals: the Acumen Pharmaceuticals page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.